GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (OTCPK:AONC) » Definitions » Preferred Stock

American Oncology Network (American Oncology Network) Preferred Stock : $65 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. American Oncology Network's preferred stock for the quarter that ended in Mar. 2024 was $65 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. American Oncology Network's Enterprise Value for the quarter that ended in Mar. 2024 was $296 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. American Oncology Network's Book Value per Share for the quarter that ended in Mar. 2024 was $-16.20.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). American Oncology Network's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-1.22.


American Oncology Network Preferred Stock Historical Data

The historical data trend for American Oncology Network's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Preferred Stock Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Preferred Stock
- - - 64.99

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Preferred Stock Get a 7-Day Free Trial - - 64.99 64.99 64.99

American Oncology Network Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


American Oncology Network  (OTCPK:AONC) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

American Oncology Network's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

American Oncology Network's Book Value per Share for the quarter that ended in Mar. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

American Oncology Network's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oncology Network Preferred Stock Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
N/A
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.
Executives
Saba Capital Management, L.p. 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein 10 percent owner 405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
David H Gould officer: Chief Financial Officer 7370 COLLEGE PARKWAY, SUITE 207, FORT MEYERS FL 33907
Erica Mallon officer: General Counsel 14543 GLOBAL PARKWAY, SUITE 110, FORT MEYERS FL 33913
Shalin Shah director 3402 W DR. MARTIN LUTHER KING JR. BLVD, TAMPA FL 33607
Vipul M Patel director 11704 SE 15TH CIRCLE, OCALA FL 34480
Todd Schonherz director, officer: Chief Executive Officer 14543 GLOBAL PARKWAY, 2ND FLOOR, FORT MEYERS FL 33913
Stephen Divers director, officer: Chief Medical Officer 133 HARMONY PARK CIRCLE, HOT SPRINGS AZ 71913
Vance Wright-browne director 22395 EDGEWATER DRIVE, PORT CHARLOTTE FL 33980
James Stith director ONE LETTERMAN DRIVE, CM200, SAN FRANCISCO CA 94129
Aea Growth Equity Fund Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Aea Growth Equity Fund (parallel) Lp 10 percent owner 520 MADISON AVE, 40TH FLOOR, NEW YORK NY 10022
Ravi Yang Sarin director C/O ARES MANAGEMENT LLC, 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES CA 90067
Brian R Hoesterey 10 percent owner C/O AEA INVESTORS LP, 666 FIFTH AVENUE, 36TH FLOOR, NEW YORK NY 10103
Kevin Nazemi director, officer: Chief Executive Officer 10485 NE 6TH ST, UNIT 3930, BELLEVUE WA 98004